Outcomes of Antineoplastic Immunotherapy at a Large Healthcare Organization: Impact of Provider, Race and Socioeconomic Status

References

• Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2(5):e192535. doi:10.1001/jamanetworkopen.2019.2535
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011;17(22):6958–6962. doi:10.1158/1078-0432.CCR-11-1595
   PubMed Web of Science ®Google Scholar
• Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148. doi:10.1016/j.ejca.2015.11.016
   PubMed Web of Science ®Google Scholar
• Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers. 2020;12(3):738. doi:10.3390/cancers12030738
   PubMed Web of Science ®Google Scholar
• Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw. 2020;18(3):230–241. doi:10.6004/jnccn.2020.0012
   PubMed Web of Science ®Google Scholar
• Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073–4126. doi:10.1200/JCO.21.01440
   PubMed Web of Science ®Google Scholar
• Verhoeven DC, Chollette V, Lazzara EH, Shuffler ML, Osarogiagbon RU, Weaver SJ. The anatomy and physiology of teaming in cancer care delivery: a conceptual framework. J Natl Cancer Inst. 2021;113(4):360–370. doi:10.1093/jnci/djaa166
   PubMedGoogle Scholar
• Noyes K, Monson JR, Rizvi I, Savastano A, Green JS, Sevdalis N. Regional multiteam systems in cancer care delivery. J Oncol Pract. 2016;12(11):1059–1066. doi:10.1200/JOP.2016.013896
   PubMed Web of Science ®Google Scholar
• American Association for Cancer Research. Cancer disparities progress report 2022; 2022.
   Google Scholar
• Bruno DS, Hess LM, Li X, Su EW, Patel M. Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States. JCO Precis Oncol. 2022;6:e2100427. doi:10.1200/PO.21.00427
   PubMed Web of Science ®Google Scholar
• Turner M, Adam MA, Sun Z, et al. Insurance status, not race, is associated with use of minimally invasive surgical approach for rectal cancer. Ann Surg. 2017;265(4):774–781. doi:10.1097/SLA.0000000000001781
   PubMed Web of Science ®Google Scholar
• Corso CD, Park HS, Kim AW, Yu JB, Husain Z, Decker RH. Racial disparities in the use of SBRT for treating early-stage lung cancer. Lung Cancer. 2015;89(2):133–138. doi:10.1016/j.lungcan.2015.05.002
   PubMed Web of Science ®Google Scholar
• Kann BH, Park HS, Johnson SB, Chiang VL, Yu JB. Radiosurgery for brain metastases: changing practice patterns and disparities in the United States. J Natl Compr Canc Netw. 2017;15(12):1494–1502. doi:10.6004/jnccn.2017.7003
   PubMed Web of Science ®Google Scholar
• Killeen SD, O’Sullivan MJ, Coffey JC, Kirwan WO, Redmond HP. Provider volume and outcomes for oncological procedures. Br J Surg. 2005;92(4):389–402. doi:10.1002/bjs.4954
   PubMed Web of Science ®Google Scholar
• Boffa DJ, Mallin K, Herrin J, et al. Survival after cancer treatment at top-ranked US cancer hospitals vs affiliates of top-ranked cancer hospitals. JAMA Netw Open. 2020;3(5):e203942. doi:10.1001/jamanetworkopen.2020.3942
   PubMed Web of Science ®Google Scholar
• Naghavi AO, Echevarria MI, Strom TJ, et al. Patient choice for high-volume center radiation impacts head and neck cancer outcome. Cancer Med. 2018;7(10):4964–4979. doi:10.1002/cam4.1756
   PubMed Web of Science ®Google Scholar
• Koshy M, Malik R, Spiotto M, Mahmood U, Weichselbaum R, Sher D. Disparities in treatment of patients with inoperable stage I non-small cell lung cancer: a population-based analysis. J Thorac Oncol. 2015;10(2):264–271. doi:10.1097/JTO.0000000000000418
   PubMed Web of Science ®Google Scholar
• Harris PA, R Taylor R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381.
   PubMed Web of Science ®Google Scholar
• NEOCANDO at the Center on Urban Poverty and Community Development. Neighborhood data warehouse; 2020. Available from: https://neocando.case.edu/neighborhood-data.html. Accessed August 17, 2023.
   Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481. doi:10.1080/01621459.1958.10501452
   Web of Science ®Google Scholar
• Cox DR. Regression models and life-tables. J R Stat Soc Series B. 1972;34(2):187–220.
   Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. doi:10.1080/01621459.1999.10474144
   Web of Science ®Google Scholar
• Hallet J, Davis L, Mahar A, et al. Benefits of high-volume medical oncology care for noncurable pancreatic adenocarcinoma: a population-based analysis. J Natl Compr Canc Netw. 2020;18(3):297–303. doi:10.6004/jnccn.2019.7361
   PubMed Web of Science ®Google Scholar
• Hallet J, Davis LE, Mahar AL, et al. Variation in receipt of therapy and survival with provider volume for medical oncology in non-curative esophago-gastric cancer: a population-based analysis. Gastric Cancer. 2020;23(2):300–309. doi:10.1007/s10120-019-01012-z
   PubMed Web of Science ®Google Scholar
• City of Hope. Why cancer care is different; 2021. Available from: https://www.cityofhope.org/breakthroughs/why-cancer-care-is-different. Accessed August 17, 2023.
   Google Scholar
• National Comprehensive Cancer Network. Non-small cell lung cancer (version 6.2022); 2022. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed August 17, 2023.
   Google Scholar
• Krimphove MJ, Tully KH, Friedlander DF, et al. Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. J Immunother Cancer. 2019;7(1):289. doi:10.1186/s40425-019-0782-y
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology. Clinical Pathways. Available from: https://old-prod.asco.org/news-initiatives/current-initiatives/cancer-care-initiatives/clinical-pathways#:~:text=High%2Dquality%20oncology%20clinical%20pathways,care%20quality%20and%20reducing%20costs. Accessed August 17, 2023.
   Google Scholar
• Daly B, Zon RT, Page RD, et al. Oncology clinical pathways: charting the landscape of pathway providers. J Oncol Pract. 2018;14(3):e194–e200. doi:10.1200/JOP.17.00033
   PubMed Web of Science ®Google Scholar
• Zon RT, Edge SB, Page RD, et al. American Society of clinical oncology criteria for high-quality clinical pathways in oncology. J Oncol Pract. 2017;13(3):207–210. doi:10.1200/JOP.2016.019836
   PubMed Web of Science ®Google Scholar
• Bosserman LD, Cianfrocca M, Yuh B, et al. Integrating academic and community cancer care and research through multidisciplinary oncology pathways for value-based care: a review and the city of hope experience. J Clin Med. 2021;10(2):188. doi:10.3390/jcm10020188
   PubMed Web of Science ®Google Scholar
• Caffrey M. From making oncology clinical pathways multidisciplinary, to adding the patient voice. Evid Based Oncol. 2020;26(9):SP306.
   Google Scholar
• Hertler A, Chau S, Khetarpal R, et al. Utilization of clinical pathways can reduce drug spend within the oncology care model. JCO Oncol Pract. 2020;16(5):e456–e63. doi:10.1200/JOP.19.00753
   PubMedGoogle Scholar
• Hu X, Lipscomb J, Graetz I. The impact of vertical integration of oncologists on cancer outcomes and healthcare costs among metastatic prostate cancer patients. J Clin Oncol. 2022;40(16_suppl):e18786–e. doi:10.1200/JCO.2022.40.16_suppl.e18786
   Web of Science ®Google Scholar
• Alpert A, Hsi H, Jacobson M. Evaluating the role of payment policy in driving vertical integration in the oncology market. Health Aff. 2017;36(4):680–688. doi:10.1377/hlthaff.2016.0830
   Web of Science ®Google Scholar
• Stamy CD, Schwartz CC, Han LP, Schwinn DA. Community and academic physicians working together in integrated health care systems. Mayo Clin Proc Innov Qual Outcomes. 2021;5(5):951–960. doi:10.1016/j.mayocpiqo.2021.06.008
   PubMedGoogle Scholar
• Karimi M, Wang C, Bahadini B, Hajjar G, Fakih M. Integrating academic and community practices in the management of colorectal cancer: the city of hope model. J Clin Med. 2020;9(6):1687. doi:10.3390/jcm9061687
   PubMed Web of Science ®Google Scholar
• Bruno D, Donner A, Kopp S, et al. Implementation of a precision medicine thoracic (PREDICT) service using reflex testing in a large academic-community practice network. J Clin Oncol. 2022;40:6572. doi:10.1200/JCO.2022.40.16_suppl.6572
   Web of Science ®Google Scholar
• Gesme DH, Wiseman M. Subspecialization in community oncology: option or necessity? J Oncol Pract. 2011;7(3):199–201. doi:10.1200/JOP.2011.000292
   PubMedGoogle Scholar
• Giaquinto AN, Miller KD, Tossas KY, Winn RA, Jemal A, Siegel RL. Cancer statistics for African American/black people 2022. CA Cancer J Clin. 2022;72(3):202–229. doi:10.3322/caac.21718
   PubMed Web of Science ®Google Scholar
• Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–580. doi:10.1038/s41571-019-0218-0
   PubMed Web of Science ®Google Scholar